Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
505
datasets available to search
ShareScore release 0.9.0
Dataset results
505 results for “carriers”
Autothermal Hydrogen Release from Liquid Organic Hydrogen Carrier Systems
Open the record for dataset details and reuse information.
Carriers of a single cystic fibrosis transmembrane conductance regulator pathogenic variant and COVID-19 in pregnancy: A retrospective longitudinal cohort study
Open the record for dataset details and reuse information.
Antiviral Tfh response by "immunotolerant" virus carriers drives antibody-mediated control of congenital infection
<p>Analysed and annotated SingleCellExperiment object </p>
Data from: The yeast mitochondrial pyruvate carrier is a hetero-dimer in its functional state
The mitochondrial pyruvate carrier (MPC) is critical for cellular homeostasis, as it is required in central metabolism for transporting pyruvate from the cytosol into the mitochondrial matrix. MPC has been implicated in many diseases and is being investigated as a drug target. A few years ago, small membrane proteins, called MPC1 and MPC2 in mammals and Mpc1, Mpc2 and Mpc3 in yeast, were proposed to form large protein complexes responsible for this function. However, the MPC complexes have never been isolated and their composition, oligomeric state and functional properties have not been defined. Here, we identify the functional unit of MPC from Saccharomyces cerevisiae. In contrast to earlier hypotheses, we demonstrate that MPC is a hetero‐dimer, not a multimeric complex. When not engaged in hetero‐dimers, the yeast Mpc proteins can also form homo‐dimers that are, however, inactive. We show that the earlier described substrate transport properties and inhibitor profiles are embodied by the hetero‐dimer. This work provides a foundation for elucidating the structure of the functional complex and the mechanism of substrate transport and inhibition.
Clinical features in X-linked myotubular myopathy carriers
<p>Objective: To characterize the spectrum of clinical features in a cohort of X-linked myotubular myopathy (XL-MTM) carriers, including prevalence, genetic features, clinical symptoms and signs, as well as associated disease burden.</p> <p>Methods: We performed a cross-sectional online questionnaire study among XL-MTM carriers. Participants were recruited from patient associations, medical centers and registries in the United Kingdom, Germany and the Netherlands. We used a custom-made questionnaire, the Checklist Individual Strength (CIS), the Frenchay Activities Index (FAI), the SF-12 Health survey and the McGill Pain Questionnaire (MPQ). Carriers were classified as manifesting or non-manifesting, based on self-reported ambulation and muscle weakness.</p> <p>Results: The prevalence of manifesting carriers in this study population (n=76) was 51%, subdivided into mild (independent ambulation, 39%), moderate (assisted ambulation, 9%) and severe (wheelchair-dependent, 3%) phenotypes. In addition to muscle weakness, manifesting carriers frequently reported fatigue (70%) and exercise intolerance (49%). Manifesting carriers scored higher on the overall CIS (p = 0.001), the fatigue sub-scale (p < 0.001) and least severe pain sub-scale (p = 0.005) than non-manifesting carriers. They scored lower on the FAI (p = 0.005) and the physical component of the SF-12 Health survey (p < 0.001).</p> <p>Conclusions: The prevalence of manifesting XL-MTM carriers may be higher than currently assumed, most having a mild phenotype and a wide variety of symptoms. Manifesting carriers are particularly affected by fatigue, limitations of daily activities, pain and reduced quality of life. Our findings should increase awareness and provide useful information for health care providers and future clinical trials.</p>
Determination of the responsivity of a predictable quantum efficient detector over a wide spectral range based on a 3D model of charge carrier recombination losses
<p>We present a method to determine the internal quantum deficiency (IQD) of a predictable quantum efficient detector (PQED) based on measured photocurrent dependence on bias voltage and a 3D simulation model of charge carrier recombination losses. The simulation model of silicon photodiodes includes wafer doping concentration, fixed charge of SiO2 layer, bulk lifetime of charge carriers and surface recombination velocity as the fitted parameters. With only one set of physical photodiode defining parameters, the simulation shows excellent agreement with experimental data at power levels from 100 μW to 1000 μW with variation in illumination beam size. We could also predict the dependence of IQD on bias voltage at the wavelength of 476 nm using photodiode parameters determined independently at 647 nm wavelength. The fitted values of doping concentration and fixed charge extracted from the simulation model are in close agreement with the expected parameter values determined earlier. At bias voltages larger than 5 V at the wavelength of 476 nm, the internal quantum efficiency of one of the tested PQEDs is measured to be 0.999 970 ± 0.000 027, where the relative expanded uncertainty of 0.000 027 is one of the lowest values ever achieved in spectral responsivity measurement of optical detectors.</p>
Geometrical magnetoresistance effect for carrier mobility extraction in InGaAs MOSFETs
<p>Dataset from gMR measurements on InGaAs MOSFETs.</p>
Kelvin Probe Force Microscopy under Variable Illumination: A Novel Technique To Unveil Charge Carrier Dynamics in GaN
<p>SPV curve in logarithmic scale; XPS results before heating, after heating, and after sputtering; SPV after days in darkness; and AFM and CPD maps (before and after heating) of larger areas with higher spatial resolution than the ones presented here (<a href="https://pubs.acs.org/doi/suppl/10.1021/acs.jpcc.3c01887/suppl_file/jp3c01887_si_001.pdf">PDF</a>)</p>
Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosoma
ClinicalTrials.gov study NCT03977584. IPD Sharing: YES. Countries: 1. Publications: 0.
Transcervical Balloon Catheters in GBS Carriers, Is It Safe? A Randomized Controlled Trial
ClinicalTrials.gov study NCT03064672. IPD Sharing: NO. Countries: 0. Publications: 1.
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
ClinicalTrials.gov study NCT04690348. IPD Sharing: YES. Countries: 1. Publications: 0.
Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy
ClinicalTrials.gov study NCT03382574. IPD Sharing: YES. Countries: 2. Publications: 0.
A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers
ClinicalTrials.gov study NCT05509153. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
The Effect of Using Multifunctional Baby Carrier With Heart Surgery
ClinicalTrials.gov study NCT07319858. IPD Sharing: NO. Countries: 1. Publications: 0.
CES1 Carriers in the PAPI Study
ClinicalTrials.gov study NCT03188705. IPD Sharing: YES. Countries: 1. Publications: 0.
Bleeding Symptoms of Carriers of Hemophilia A and B
ClinicalTrials.gov study NCT01029808. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis
ClinicalTrials.gov study NCT01582880. IPD Sharing: NO. Countries: 1. Publications: 0.
Carriere Motion Appliance* Versus In-office Sectional Appliance
ClinicalTrials.gov study NCT05204654. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Estimation of the Carrier Frequency and Incidence of Smith-Lemli-Opitz Syndrome in African Americans
ClinicalTrials.gov study NCT00017732. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Clinical Implementation of Carrier Status Using Next Generation Sequencing
ClinicalTrials.gov study NCT01902901. IPD Sharing: YES. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.